---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-001711"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2025-01-07T23:59:59+00:00"
generated_at: "2026-05-28T08:54:59.470869+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics appoints Gene Mack as permanent CEO, Fuggetta as Principal Financial Officer

## Summary
- Gene Mack, interim CEO since June 2024, appointed President and CEO and Board member effective Jan 6, 2025.
- Mack resigns as CFO; receives $500K base salary, 50% target bonus, and option for 271,325 shares at $2.44.
- Gianluca Fuggetta, VP of Finance, becomes SVP Finance and Principal Financial Officer; base salary CHF 200K.
- Mack brings 25+ years biotech experience; Fuggetta previously served as interim Principal Financial Officer in 2024.

## SEC filing metadata
- accession: 0001104659-25-001711
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2025-01-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465925001711/0001104659-25-001711-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465925001711/tm252048d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-001711
- JSON: https://secwatch.observer/filing/0001104659-25-001711.json
- Plain text: https://secwatch.observer/filing/0001104659-25-001711.txt

## Key facts
- Executive change
  Gene Mack was appointed as President and Chief Executive Officer at Gain Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: announced that Gene Mack has been appointed the Company’s President and Chief Executive Officer and a member of the Company’s board of directors (the “Board of Directors”), effective January 6, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000110465925001711/0001104659-25-001711-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.